Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy.
Carnovale C, Brusadelli T, Zuccotti G, Beretta S, Sullo MG, Capuano A, Rossi F, Moschini M, Mugelli A, Vannacci A, Laterza M, Clementi E, Radice S; MEAP Group. Carnovale C, et al. Among authors: mugelli a. Expert Opin Drug Saf. 2014 Sep;13 Suppl 1:S1-8. doi: 10.1517/14740338.2014.928692. Expert Opin Drug Saf. 2014. PMID: 25171154
The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?
Trifirò G, Gini R, Barone-Adesi F, Beghi E, Cantarutti A, Capuano A, Carnovale C, Clavenna A, Dellagiovanna M, Ferrajolo C, Franchi M, Ingrasciotta Y, Kirchmayer U, Lapi F, Leone R, Leoni O, Lucenteforte E, Moretti U, Mugelli A, Naldi L, Poluzzi E, Rafaniello C, Rea F, Sultana J, Tettamanti M, Traversa G, Vannacci A, Mantovani L, Corrao G. Trifirò G, et al. Among authors: mugelli a. Drug Saf. 2019 Mar;42(3):347-363. doi: 10.1007/s40264-018-0732-5. Drug Saf. 2019. PMID: 30269245 Free article. Review.
Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy.
Lapi F, Tuccori M, Motola D, Pugi A, Vietri M, Montanaro N, Vaccheri A, Leoni O, Cocci A, Leone R, Conforti A, Moretti U, Sessa E, Mazzaglia G, Mugelli A, Mazzei T, Vannacci A. Lapi F, et al. Among authors: mugelli a. Drug Saf. 2010 Sep 1;33(9):789-99. doi: 10.2165/11536810-000000000-00000. Drug Saf. 2010. PMID: 20701411
Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study.
Lombardi N, Crescioli G, Bettiol A, Marconi E, Vitiello A, Bonaiuti R, Calvani AM, Masi S, Lucenteforte E, Mugelli A, Giovannelli L, Vannacci A. Lombardi N, et al. Among authors: mugelli a. BMC Pharmacol Toxicol. 2018 Apr 16;19(1):16. doi: 10.1186/s40360-018-0207-4. BMC Pharmacol Toxicol. 2018. PMID: 29661234 Free PMC article.
Cardiovascular and metabolic safety profiles of the fluoroquinolones.
Pugi A, Longo L, Bartoloni A, Rossolini GM, Mugelli A, Vannacci A, Lapi F. Pugi A, et al. Among authors: mugelli a. Expert Opin Drug Saf. 2012 Jan;11(1):53-69. doi: 10.1517/14740338.2011.624512. Epub 2011 Sep 30. Expert Opin Drug Saf. 2012. PMID: 21958023 Review.
274 results